How Many Rounds of Shots to Babies Get First 3 Months

Legend

Range of recommended ages for all children

Range of recommended ages for grab-upward vaccination

Range of recommended ages for certain high-risk groups

Recommended vaccination tin begin in this historic period group

Recommended vaccination based on shared clinical decision-making

No recommendation/Not applicable

Nascency to xv Months

child vaccine schedule tabular array ane

Vaccine	Birth	1 mo	two mos	4 mos	6 mos	9 mos	12 mos	fifteen mos
Hepatitis B (HepB)	1st dose	←iind dose→			←3rd dose→
Rotavirus (RV) RV1 (2-dose series); RV5 (three-dose series)			1st dose	2nd dose	See notes
Diphtheria, tetanus, & acellular pertussis (DTaP: <seven yrs)			onest dose	2nd dose	3rd dose			←4thursday dose→
Haemophilus influenzae blazon b (Hib)			1st dose	2nd dose	See notes		←iiird or 4th dose, See notes→
Pneumococcal conjugate (PCV13)			ist dose	2nd dose	3rd dose		←fourth dose→
Inactivated poliovirus (IPV: <18 yrs)			1st dose	twond dose	←3rd dose→
Influenza (IIV4)					Annual vaccination i or 2 doses
Influenza (LAIV4)
Measles, mumps, rubella (MMR)					See notes		←1st dose→
Varicella (VAR)							←ist dose→
Hepatitis A (HepA)					Run across notes		←ii-dose series, See notes→
Tetanus, diphtheria, & acellular pertussis (Tdap: ≥seven yrs)
Human papillomavirus (HPV)
Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)			See notes
Meningococcal B (MenB-4C, MenB-FHbp)
Pneumococcal polysaccharide (PPSV23)
Dengue (DEN4CYD; nine-16 yrs)

eighteen Months to xviii Years

kid vaccine schedule table 2

Vaccines	18 mos	nineteen-23 mos	2-3 yrs	4-vi yrs		seven-10 yrs		eleven-12 yrs	13-15 yrs	sixteen yrs	17-18 yrs
Hepatitis B (HepB)	←iiird dose→
Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose serial)
Diphtheria, tetanus, & acellular pertussis (DTaP: <vii yrs)	←fourth dose→			vth dose
Haemophilus influenzae type b (Hib)
Pneumococcal conjugate (PCV13)
Inactivated poliovirus (IPV: <18 yrs)	←3rd dose→			fourthursday dose
Influenza (IIV4)	Almanac vaccination 1 or ii doses						Annual vaccination ane dose only
Flu (LAIV4)			Annual vaccination 1 or 2 doses				Annual vaccination 1 dose only
Measles, mumps, rubella (MMR)				iind dose
Varicella (VAR)				2nd dose
Hepatitis A (HepA)	← 2-dose series, Run across notes→
Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs)								i dose
Man papillomavirus (HPV)								See notes
Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)	See notes							1st dose		2nd dose
Meningococcal B (MenB-4C, MenB-FHbp)								Meet notes
Pneumococcal polysaccharide (PPSV23)			See notes
Dengue (DEN4CYD; ix-sixteen yrs)							Seropositive in endemic areas only (See notes)

Dengue Vaccination

• Historic period 9–xvi years living in dengue endemic areas AND have laboratory confirmation of previous dengue infection
  • 3-dose serial administered at 0, six, and 12 months
• Endemic areas include Puerto Rico, American Samoa, US Virgin Islands, Federated States of Micronesia, Republic of Marshall Islands, and the Republic of Palau. For updated guidance on dengue endemic areas and pre-vaccination laboratory testing run across https://world wide web.cdc.gov/mmwr/volumes/70/rr/rr7006a1.htm and https://world wide web.cdc.gov/dengue/vaccine/hcp/index.html.

For contraindications and precautions to dengue vaccination, see Dengue Appendix

Diphtheria, tetanus, and pertussis (DTaP) vaccination
(minimum historic period: half dozen weeks [4 years for Kinrix® or Quadracel®])

• 5-dose series at age 2, 4, half-dozen, xv–18 months, 4–half-dozen years
  • Prospectively: Dose four may exist administered equally early every bit age 12 months if at to the lowest degree 6 months take elapsed since dose iii.
  • Retrospectively: A quaternary dose that was inadvertently administered every bit early on as historic period 12 months may be counted if at least 4 months have elapsed since dose iii.

• Dose 5 is not necessary if dose 4 was administered at historic period 4 years or older and at to the lowest degree 6 months after dose 3.
• For other take hold of-upwards guidance, see Tabular array 2.

• Wound management in children less than age 7 years with history of 3 or more than doses of tetanus-toxoid-containing vaccine: For all wounds except clean and minor wounds, administer DTaP if more than v years since last dose of tetanus-toxoid-containing vaccine. For detailed information, run across www.cdc.gov/mmwr/volumes/67/rr/rr6702a1.htm.

For contraindications and precautions to Diphtheria, tetanus, pertussis (DTaP) vaccination, see DTaP Appendix

Haemophilus influenzae blazon b vaccination
(minimum age: half-dozen weeks)

•  ActHIB^®, Hiberix^®, Pentacel^®, or Vaxelis^®: 4-dose serial (3 dose main serial at historic period 2, 4, and 6 months, followed past a booster dose* at age 12–15 months)
  • *Vaxelis^® is not recommended for utilise as a booster dose. A different Hib-containing vaccine should be used for the booster dose.
• PedvaxHIB^®: iii-dose series (2-dose principal series at age 2 and 4 months, followed by a booster dose at age 12–xv months)

• Dose i at historic period 7–eleven months: Administer dose 2 at to the lowest degree four weeks after and dose 3 (final dose) at historic period 12–15 months or 8 weeks later on dose 2 (whichever is later).
• Dose 1 at age 12–fourteen months: Administrate dose 2 (final dose) at least eight weeks subsequently dose 1.
• Dose 1 before age 12 months and dose ii earlier historic period 15 months: Administer dose iii (last dose) at least 8 weeks subsequently dose 2.
• 2 doses of PedvaxHIB^® before age 12 months: Administer dose 3 (terminal dose) at historic period 12–59 months and at least 8 weeks later dose two.
• ane dose administered at age xv months or older: No further doses needed
• Unvaccinated at age 15–59 months: Administer 1 dose.
• Previously unvaccinated children historic period lx months or older who are not considered high gamble: Exercise not require catch-up vaccination

For other catch-upwardly guidance, see Table 2. Vaxelis^® can be used for grab-upwardly vaccination in children less than age 5 years. Follow the catch-upwards schedule even if Vaxelis^® is used for ane or more doses. For detailed information on apply of Vaxelis run across www.cdc.gov/mmwr/volumes/69/wr/mm6905a5.htm.

• Chemotherapy or radiations treatment:

  Age 12–59 months

  • Unvaccinated or only one dose earlier age 12 months: 2 doses, 8 weeks autonomously
  • 2 or more doses earlier age 12 months: i dose at least viii weeks after previous dose

  Doses administered within xiv days of starting therapy or during therapy should be repeated at least three months after therapy completion.

• Hematopoietic stalk cell transplant (HSCT):
  • iii-dose serial 4 weeks autonomously starting half-dozen to 12 months after successful transplant regardless of Hib vaccination history
• Anatomic or functional asplenia (including sickle prison cell disease):

  Historic period 12–59 months

  • Unvaccinated or just 1 dose before age 12 months: 2 doses, 8 weeks apart
  • ii or more doses before age 12 months: 1 dose at least 8 weeks after previous dose

  Unvaccinated* persons age 5 years or older

  • 1 dose
• Elective splenectomy:

  Unvaccinated* persons age 15 months or older

  • i dose (preferably at least 14 days earlier procedure)
• HIV infection:

  Age 12–59 months

  • Unvaccinated or just 1 dose before historic period 12 months: 2 doses, 8 weeks apart
  • 2 or more doses earlier age 12 months: 1 dose at least 8 weeks after previous dose

  Unvaccinated* persons age 5–18 years

  • 1 dose
• Immunoglobulin deficiency, early component complement deficiency:

  Age 12–59 months

  • Unvaccinated or simply 1 dose before age 12 months: 2 doses, viii weeks autonomously
  • 2 or more doses earlier historic period 12 months: 1 dose at least 8 weeks afterwards previous dose

*Unvaccinated = Less than routine serial (through age 14 months) OR no doses (age 15 months or older)

For contraindications and precautions to Haemophilus influenzae type b (Hib) vaccination, see Hib Appendix

Hepatitis A vaccination
(minimum age: 12 months for routine vaccination)

• two-dose series (minimum interval: 6 months) at age 12–23 months

• Unvaccinated persons through age 18 years should consummate a 2-dose series (minimum interval: vi months).
• Persons who previously received i dose at age 12 months or older should receive dose ii at least 6 months later dose 1.
• Adolescents age eighteen years or older may receive the combined HepA and HepB vaccine, Twinrix^® , every bit a iii-dose series (0, i, and 6 months) or four-dose series (3 doses at 0, seven, and 21–30 days, followed by a booster dose at 12 months).

• Persons traveling to or working in countries with loftier or intermediate endemic hepatitis A
  (http://www.cdc.gov/travel/)
  • Infants historic period six–11 months: 1 dose earlier departure; revaccinate with 2 doses, separated past at least 6 months, between historic period 12–23 months.
  • Unvaccinated historic period 12 months or  older: Administer dose i as shortly as travel is considered.

For contraindications and precautions to Hepatitis A (HepA) vaccination, run into HepA Appendix

Hepatitis B vaccination
(minimum historic period: nativity)

• Female parent is HBsAg-negative:
  • All medically stable infants ≥ii,000 grams: 1 dose within 24 hours of nascency
  • Infants <2,000 grams: Administer 1 dose at chronological historic period i month or hospital discharge (whichever is earlier and even if weight is still <two,000 grams).
• Mother is HBsAg-positive:
  • Administrate HepB vaccine and hepatitis B immune globulin (HBIG)(in separate limbs) within 12 hours of birth, regardless of birth weight. For infants <ii,000 grams, administer three additional doses of vaccine (total of 4 doses) first at age i calendar month.
  • Test for HBsAg and anti-HBs at age 9–12 months. If HepB series is delayed, examination ane–2 months after terminal dose.
• Mother'southward HBsAg status is unknown:
  • Administer HepB vaccine within 12 hours of nascence, regardless of birth weight.
  • For infants <2,000 grams, administer HBIG in addition to HepB vaccine (in carve up limbs) within 12 hours of birth. Administer 3 additional doses of vaccine (total of 4 doses) beginning at age one month.
  • Determine mother's HBsAg status every bit soon every bit possible. If mother is HBsAg-positive, administer HBIG to infants ≥2,000 grams as soon as possible, just no later than 7 days of age.

• 3-dose series at age 0, 1–2, 6–eighteen months (use monovalent HepB vaccine for doses administered earlier age six weeks)
• Infants who did not receive a birth dose should begin the serial as before long equally feasible (see Table ii).
• Assistants of four doses is permitted when a combination vaccine containing HepB is used after the birth dose.
• Minimum age for the final (3rd or quaternary ) dose: 24 weeks
• Minimum intervals: dose 1 to dose two: 4 weeks / dose 2 to dose three: 8 weeks / dose 1 to dose 3: sixteen weeks (when 4 doses are administered, substitute "dose 4" for "dose 3" in these calculations)

• Unvaccinated persons should complete a 3-dose series at 0, 1–2, 6 months.
• Adolescents age eleven–xv years may utilize an alternative 2-dose schedule with at least 4 months between doses (developed formulation Recombivax HB^® only).
• Adolescents age 18 years or older may receive a 2-dose series of HepB (Heplisav-B^®) at least 4 weeks apart.
• Adolescents age 18 years or older may receive the combined HepA and HepB vaccine, Twinrix^® , as a 3-dose serial (0, 1, and 6 months) or four-dose serial (3 doses at 0, vii, and 21–thirty days, followed past a booster dose at 12 months).
• For other catch-upward guidance, encounter Tabular array two.

• Revaccination is not generally recommended for persons with a normal allowed status who were vaccinated every bit infants, children, adolescents, or adults.
• Post-vaccination serology testing and revaccination (if anti-HBs < 10mlU/mL) is recommended for certain populations, including:
  • Infants built-in to HBsAg-positive mothers
  • Hemodialysis patients
  • Other immunocompromised persons

For detailed revaccination recommendations, see http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html.

For contraindications and precautions to Hepatitis B (HepB) vaccination, meet HepB Appendix

Human papillomavirus vaccination
(minimum historic period: 9 years)

• HPV vaccination routinely recommended at age 11–12 years (can start at age ix years) and grab-up HPV vaccination recommended for all persons through age 18 years if not adequately vaccinated
• ii- or 3-dose series depending on historic period at initial vaccination:
  • Age ix –14 years at initial vaccination: 2-dose serial at 0, 6–12 months (minimum interval: 5 months; repeat dose if administered too soon)
  • Historic period 15 years or older at initial vaccination: 3-dose series at 0, 1–2 months, half dozen months (minimum intervals: dose 1 to dose 2: 4 weeks / dose ii to dose iii: 12 weeks / dose i to dose three: five months; repeat dose if administered too shortly)
• Interrupted schedules: If vaccination schedule is interrupted, the serial does not need to be restarted.
• No additional dose recommended when whatsoever HPV vaccine serial has been completed using the recommended dosing intervals.

• Immunocompromising conditions, including HIV infection: iii-dose series, even for those who initiate vaccination at historic period 9 through fourteen years.
• History of sexual abuse or assault: Start at historic period nine years.
• Pregnancy: Pregnancy testing not needed before vaccination; HPV vaccination not recommended until after pregnancy; no intervention needed if vaccinated while pregnant

For contraindications and precautions to Human papillomavirus (HPV) vaccination, meet HPV Appendix

Influenza vaccination
(minimum age: 6 months [IIV], 2 years [LAIV4], 18 years [recombinant flu vaccine, RIV4])

• Apply any influenza vaccine appropriate for age and health status annually:
  • 2 doses, separated by at least 4 weeks, for children age 6 months–8 years who accept received fewer than 2 flu vaccine doses before July 1, 2021, or whose flu vaccination history is unknown (administer dose two fifty-fifty if the child turns 9 between receipt of dose 1 and dose 2)
  • ane dose for children age half dozen months–viii years who have received at least 2 flu vaccine doses earlier July 1, 2021
  • 1 dose for all persons age 9 years or older
• For the 2021-2022 season, see www.cdc.gov/mmwr/volumes/70/rr/rr7005a1.htm.
• For the 2022–23 season, see the 2022–23 ACIP flu vaccine recommendations.

• Egg allergy, hives only: Any influenza vaccine advisable for historic period and wellness status annually
• Egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or some other emergency medical intervention: meet Appendix listing contraindications and precautions.
• Astringent allergic reaction (due east.grand., anaphylaxis) to a vaccine component or a previous dose of any influenza vaccine: run into Appendix list contraindications and precautions

For contraindications and precautions to Influenza vaccination, see IIV4 Appendix, LAIV4 Appendix, ccIIV4 Appendix, and RIV4 Appendix.

Measles, mumps, and rubella vaccination
(minimum age: 12 months for routine vaccination)

• 2-dose series at age 12–15 months, age 4–6 years
• MMR or MMRV may be administered

Note: For dose 1 in children age 12–47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.

• Unvaccinated children and adolescents: two-dose serial at least iv weeks apart
• The maximum age for use of MMRV is 12 years.
• Minimum interval between MMRV doses: 3 months

International travel

• Infants age 6–11 months:1 dose before departure; revaccinate with 2-dose series at age 12–15 months (12 months for children in high-run a risk areas) and dose 2 as early as 4 weeks afterward.
• Unvaccinated children age 12 months or older:2-dose series at least 4 weeks apart before departure

For contraindications and precautions to Measles, mumps, rubella (MMR), run across MMR Appendix

Meningococcal serogroup A, C, W, Y vaccination (minimum age: ii months [MenACWY-CRM, Menveo], 9 months [MenACWY-D, Menactra], 2 years [MenACWY-TT, MenQuadfi])

• 2-dose series at age xi–12 years, 16 years

• Historic period 13–15 years: ane dose at present and booster at age 16–18 years (minimum interval: 8 weeks)
• Historic period 16–18 years: 1 dose

Anatomic or functional asplenia (including sickle prison cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.k., eculizumab, ravulizumab) use:

• Menveo
  • Dose 1 at age two months: 4-dose series (additional 3 doses at age 4, 6 and 12 months)
  • Dose 1 at age 3–vi months: 3- or iv- dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age vii months or older, followed by an additional dose at least 12 weeks after and after age 12 months)
  • Dose 1 at age vii–23 months: 2-dose series (dose 2 at least 12 weeks after dose i and after age 12 months)
  • Dose 1 at age 24 months or older: ii-dose serial at least viii weeks apart
• Menactra
  • Persistent complement component deficiency or complement inhibitor utilise:
    • Age 9–23 months: two-dose series at least 12 weeks apart
    • Age 24 months or older: ii-dose serial at to the lowest degree 8 weeks apart
  • Anatomic or functional asplenia, sickle prison cell illness, or HIV infection:
    • Age 9–23 months: Not recommended
    • Age 24 months or older: 2-dose series at least viii weeks apart
    • Menactra^® must be administered at least 4 weeks after completion of PCV13 serial.
• MenQuadfi^®
  • Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart

Travel in countries with hyperendemic or epidemic meningococcal affliction, including countries in the African meningitis belt or during the Hajj
(www.cdc.gov/travel/):

• Children less than age 24 months:
  • Menveo^® (age 2–23 months)
    • Dose 1 at historic period 2 months: 4-dose series (additional 3 doses at age 4, 6 and 12 months)
    • Dose 1 at age 3–half-dozen months: 3- or 4- dose series (dose two [and dose three if applicable] at least 8 weeks afterwards previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and subsequently age 12 months)
    • Dose i at age 7–23 months: ii-dose series (dose 2 at to the lowest degree 12 weeks after dose one and after historic period 12 months)
  • Menactra^® (age 9–23 months)
    
    • 2-dose series (dose 2 at least 12 weeks subsequently dose 1; dose 2 may exist administered as early every bit eight weeks subsequently dose 1 in travelers)
• Children historic period 2 years or older: one dose Menveo^® , Menactra^®, or MenQuadfi^®

Starting time-yr college students who live in residential housing (if not previously vaccinated at historic period 16 years or older) or military machine recruits:

• one dose Menveo^®,, Menactra^®, or MenQuadfi^®

Boyish vaccination of children who received MenACWY prior to age ten years:

• Children for whom boosters are recommended because of an ongoing increased risk of meningococcal disease (e.g., those with complement deficiency, HIV, or asplenia): Follow the booster schedule for persons at increased risk.
• Children for whom boosters are not recommended (east.g., a healthy child who received a single dose for travel to a state where meningococcal affliction is endemic): Administer MenACWY according to the recommended boyish schedule with dose 1 at age 11–12 years and dose two at age 16 years.

Notation: Menactra^® should be administered either before or at the same time as DTaP. MenACWY vaccines may be administered simultaneously with MenB vaccines if indicated, merely at a different anatomic site, if feasible.

For MenACWY booster dose recommendations for groups listed under "Special situations" and in an outbreak setting and  boosted meningococcal vaccination information, see world wide web.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.

For contraindications and precautions to Meningococcal ACWY (MenACWY)
[MenACWY-CRM (Menveo^®); MenACWY-D (Menactra^®); MenACWY-TT (MenQuadfi^®)], meet MenACWY Appendix

Meningococcal serogroup B vaccination
(minimum historic period: 10 years [MenB-4C, Bexsero^®; MenB-FHbp, Trumenba^®])

• Adolescents not at increased risk age 16–23 years (preferred age xvi–18 years) based on shared clinical decision-making:
  • Bexsero^®: ii-dose series at least 1 month apart
  • Trumenba^®: two-dose serial at least 6 months autonomously; if dose 2 is administered before than 6 months, administrate a 3^rd dose at least 4 months later on dose 2.

Anatomic or functional asplenia (including sickle cell illness), persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab) use:

• Bexsero^®: 2-dose serial at least 1 month apart
• Trumenba^®: 3-dose series at 0, i–2, 6 months

Note: Bexsero^®  andTrumenba^®  are non interchangeable; the same product should be used for all doses in a series.

For MenBbooster dose recommendations for groups listed under "Special situations" and in an outbreak setting and boosted meningococcal vaccination data, see www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm.

For contraindications and precautions to Meningococcal B (MenB)
[MenB-4C (Bexsero^®); MenB-FHbp (Trumenba^®)], see MenB Appendix

Pneumococcal vaccination
(minimum historic period: 6 weeks [PCV13], 2 years [PPSV23])

• 4-dose series at age 2, four, six, 12–15 months

• ane dose for healthy children age 24–59 months with whatsoever incomplete* PCV13 series
• For other catch-up guidance, run across Table ii.

* Incomplete series = Not having received all doses in either the recommended series or an age-advisable take hold of-up series Encounter Tables 8, 9, and xi in the ACIP pneumococcal vaccine recommendations (www.cdc.gov/mmwr/pdf/rr/rr5911.pdfpdf icon ) for complete schedule details.

Underlying conditions below: When both PCV13 and PPSV23 are indicated, administer PCV13 get-go. PCV13 and PPSV23 should non be administered during same visit.

Chronic heart affliction (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma treated with loftier-dose, oral corticosteroids); diabetes mellitus:

Age ii–5 years

• Any incomplete* series with:
  • iii PCV13 doses: 1 dose PCV13 (at least viii weeks subsequently any prior PCV13 dose)
  • Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks later the most recent dose and administered 8 weeks autonomously)
• No history of PPSV23: 1 dose PPSV23 (at least viii weeks afterward completing all recommended PCV13 doses)

Age six–eighteen years

• No history of PPSV23: 1 dose PPSV23 (at least 8 weeks afterwards completing all recommended PCV13 doses)

Cerebrospinal fluid leak, cochlear implant:

Age ii–five years

• Any incomplete* series with:
  • iii PCV13 doses: 1 dose PCV13 (at least 8 weeks subsequently any prior PCV13 dose)
  • Less than 3 PCV13 doses: two doses PCV13 (8 weeks after the most recent dose and administered 8 weeks apart)
• No history of PPSV23: ane dose PPSV23 (at least 8 weeks after whatever prior PCV13 dose)

Age 6–18 years

• No history of either PCV13 or PPSV23: 1 dose PCV13, 1 dose PPSV23 at least viii weeks later
• Whatever PCV13 but no PPSV23: 1 dose PPSV23 at least eight weeks after the most recent dose of PCV13
• PPSV23 only no PCV13: ane dose PCV13 at to the lowest degree 8 weeks after the most contempo dose of PPSV23

Sickle prison cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or caused immunodeficiency; HIV infection; chronic renal failure; nephrotic syndrome; malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and other diseases associated with treatment with immunosuppressive drugs or radiation therapy; solid organ transplantation; multiple myeloma:

Age ii–five years

• Any incomplete* series with:
  • three PCV13 doses: 1 dose PCV13 (at to the lowest degree 8 weeks later on whatever prior PCV13 dose)
  • Less than 3 PCV13 doses: 2 doses PCV13 (8 weeks later on the near contempo dose and administered viii weeks autonomously)
• No history of PPSV23: 1 dose PPSV23 (at to the lowest degree 8 weeks after whatever prior PCV13 dose) and a dose 2 of PPSV23 5 years later

Historic period six–18 years

• No history of either PCV13 or PPSV23: 1 dose PCV13, 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks later PCV13 and dose 2 of PPSV23 administered at least v years after dose i of PPSV23)
• Any PCV13 just no PPSV23: 2 doses PPSV23 (dose 1 of PPSV23 administered 8 weeks later the most recent dose of PCV13 and dose 2 of PPSV23 administered at to the lowest degree 5 years subsequently dose i of PPSV23)
• PPSV23 just no PCV13: 1 dose PCV13 at least viii weeks later the virtually recent PPSV23 dose and a dose 2 of PPSV23 administered 5 years after dose i of PPSV23 and at least 8 weeks after a dose of PCV13

Chronic liver disease, alcoholism:

Age 6–xviii years

• No history of PPSV23: i dose PPSV23 (at least 8 weeks afterward any prior PCV13 dose)

*Incomplete serial = Not having received all doses in either the recommended series or an age-appropriate grab-upwards series. Encounter Tables eight, nine, and 11 in the ACIP pneumococcal vaccine recommendations (www.cdc.gov/mmwr/pdf/rr/rr5911.pdfpdf icon ) for complete schedule details.

For contraindications and precautions to Pneumococcal conjugate (PCV13), see PCV13 Appendix and Pneumococcal polysaccharide (PPSV23), see PPSV23 Appendix

Poliovirus vaccination
(minimum age: 6 weeks)

• 4-dose series at ages 2, 4, vi–18 months, four–6 years; administrate the last dose on or after age iv years and at least vi months later on the previous dose.
• iv or more doses of IPV tin can be administered earlier age iv years when a combination vaccine containing IPV is used. Notwithstanding, a dose is still recommended on or after age iv years and at least 6 months after the previous dose.

• In the commencement half-dozen months of life, use minimum ages and intervals only for travel to a polio-endemic region or during an outbreak.
• IPV is not routinely recommended for U.Southward. residents age eighteen years or older.

Serial containing oral polio vaccine (OPV), either mixed OPV-IPV or OPV-only serial:

• Full number of doses needed to complete the series is the same as that recommended for the U.S. IPV schedule. Encounter www.cdc.gov/mmwr/volumes/66/wr/mm6601a6.htm.
• Only trivalent OPV (tOPV) counts toward the U.S. vaccination requirements.
  • Doses of OPV administered before April one, 2016, should be counted (unless specifically noted every bit administered during a campaign).
  • Doses of OPV administered on or later on April 1, 2016, should not be counted.
  • For guidance to assess doses documented as "OPV," come across www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm.
• For other catch-up guidance, come across Table two.

For contraindications and precautions to Poliovirus vaccine, inactivated (IPV), see Appendix

Rotavirus vaccination
(minimum age: 6 weeks)

• Rotarix^®: 2-dose series at age 2 and 4 months
• RotaTeq^®: iii-dose series at age two, four, and 6 months
• If whatever dose in the serial is eitherRotaTeq^®  or unknown, default to three-dose series.

• Do not showtime the series on or afterwards historic period fifteen weeks, 0 days.
• The maximum age for the last dose is viii months, 0 days.
• For other catch-upward guidance, see Table two.

For contraindications and precautions to Rotavirus (RV) [RV1 (Rotarix®), RV5 (RotaTeq®)], encounter Rotavirus Appendix

Tetanus, diphtheria, and pertussis (Tdap) vaccination
(minimum age: xi years for routine vaccination, 7 years for catch-upwards vaccination)

• Adolescents age 11–12 years: ane dose Tdap
• Pregnancy:one dose Tdap during each pregnancy, preferably in early part of gestational weeks 27–36.
• Tdap may be administered regardless of the interval since the last tetanus- and diphtheria-toxoid-containing vaccine.

• Adolescents age 13–xviii years who have not received Tdap: 1 dose Tdap, and so Td or Tdap booster every 10 years
• Persons historic period vii–18 years not fully vaccinated* with DTaP: i dose Tdap as part of the catch-upward series (preferably the beginning dose); if additional doses are needed, use Td or Tdap.
• Tdap administered at age 7–ten years
  • Children historic period 7–nine years who receive Tdap should receive the routine Tdap dose at age eleven–12 years.
  • Children age x years who receive Tdap do not demand  the routine Tdap dose at age xi–12 years.
• DTaP inadvertently administered  on or after age 7 years:
  • Children age 7–ix years: DTaP may count as part of catch-up series. Administer routine Tdap dose at age xi–12 years.
  • Children historic period ten–18 years: Count dose of DTaP as the adolescent Tdap booster.
• For other catch-up guidance, see Table 2.

*Fully vaccinated = 5 valid doses of DTaP OR iv valid doses of DTaP if dose 4 was administered at historic period four years or older.

• Wound direction in persons historic period 7 years or older with history of three or more than doses of tetanus-toxoid-containing vaccine: For clean and minor wounds, administer Tdap or Td if more than ten years since last dose of tetanus-toxoid-containing vaccine; for all other wounds, administer Tdap or Td if more than v years since last dose of tetanus-toxoid-containing vaccine. Tdap is preferred for persons age xi years or older who have not previously received Tdap or whose Tdap history is unknown. If a tetanus-toxoid-containing vaccine is indicated for a meaning adolescent, use Tdap.
• For detailed data, see world wide web.cdc.gov/mmwr/volumes/69/wr/mm6903a5.htm.

For contraindications and precautions to Tetanus, diphtheria, and acellular pertussis (Tdap) and Tetanus, diphtheria (Td), see Tdap and Td Appendix

Varicella vaccination
(minimum age: 12 months)

• 2-dose series at age 12–15 months, 4–6 years
• VAR or MMRV may be administered*
• Dose 2 may be administered as early on every bit 3 months after dose one (a dose inadvertently administered after at least 4weeks may be counted as valid)

*Notation: For dose one in children historic period 12–47 months, it is recommended to administer MMR and varicella vaccines separately. MMRV may be used if parents or caregivers express a preference.

• Ensure persons age 7–eighteen years without bear witness of immunity (encounterMMWRat www.cdc.gov/mmwr/pdf/rr/rr5604.pdfpdf icon  ) have a 2-dose serial:
  • Age 7–12 years: routine interval: 3 months (a dose inadvertently administered afterwards at least iv weeks may exist counted every bit valid)
  • Age 13 years and older: routine interval: 4–viii weeks (minimum interval: 4 weeks)
  • The maximum age for use of MMRV is 12 years.

For contraindications and precautions to Varicella (VAR), see VAR Appendix

Appendix - Guide to Contraindications and Precautions to Commonly Used Vaccines

Adapted from Table 4-i in Advisory Committee on Immunization Practices (ACIP) General All-time Exercise Guidelines for Immunization: Contraindication and Precautions and ACIP'southward Recommendations for the Prevention and Control of 2021-22 seasonal influenza with Vaccines.

Contraindications^one

• Astringent allergic reaction (e.grand., anaphylaxis) later on a previous dose or to a vaccine component³
• Severe immunodeficiency (e.thousand., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)

Precautions²

• Pregnancy
• HIV infection without prove of severe immunosuppression
• Moderate or astringent acute illness with or without fever

Vaccine

Diphtheria, tetanus, pertussis (DTaP)

Tetanus, diphtheria (DT)

Contraindications¹

• Severe allergic reaction (due east.yard., anaphylaxis) after a previous dose or to a vaccine componentⁱⁱⁱ
• For DTaP only: Encephalopathy (e.m., blackout, decreased level of consciousness, prolonged seizures) non attributable to another identifiable cause within 7 days of administration of previous dose of DTP or DTaP

Precautions²

• Guillain-Barré syndrome (GBS) within 6 weeks later previous dose of tetanus-toxoid–containing vaccine
• History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid— containing or tetanus-toxoid– containing vaccine; defer vaccination until at least 10 years take elapsed since the terminal tetanus-toxoid- containing vaccine
• For DTaP only: Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy; defer DTaP until neurologic status clarified and stabilized
• Moderate or severe astute illness with or without fever

Vaccine

Haemophilus influenzae type b (Hib)

Contraindications^ane

• Astringent allergic reaction (eastward.g., anaphylaxis) after a previous dose or to a vaccine component³
• For Hiberix, ActHib, and PedvaxHIB only: History of astringent allergic reaction to dry out natural latex
• Historic period <vi weeks

Precautionsⁱⁱ

• Moderate or severe acute illness with or without fever

Vaccine

Hepatitis A (HepA)

Contraindications¹

• Severe allergic reaction (eastward.m., anaphylaxis) after a previous dose or to a vaccine componentⁱⁱⁱ including neomycin

Precautions^two

• Moderate or severe acute illness with or without fever

Vaccine

Hepatitis B (HepB)

Contraindications¹

• Severe allergic reaction (due east.g., anaphylaxis) after a previous dose or to a vaccine componentⁱⁱⁱ including yeast
• For Heplisav-B only: Pregnancy

Precautions²

• Moderate or severe acute illness with or without fever

Vaccine

Hepatitis A- Hepatitis B vaccine [HepA-HepB, (Twinrix^®)]

Contraindicationsⁱ

• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³ including neomycin and yeast

Precautions²

• Moderate or astringent acute illness with or without fever

Vaccine

Man papillomavirus (HPV)

Contraindications¹

• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine componentⁱⁱⁱ

Precautions^two

• Moderate or severe acute affliction with or without fever

Vaccine

Influenza, egg-based, inactivated injectable (IIV4)

Contraindications¹

• Severe allergic reaction (e.grand., anaphylaxis) after previous dose of whatsoever influenza vaccine (i.eastward., any egg-based IIV, ccIIV, RIV, or LAIV of any valency)
• Astringent allergic reaction (e.g., anaphylaxis) to any vaccine componentⁱⁱⁱ (excluding egg)

Precautions²

• Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any blazon of influenza vaccine
• Persons with egg allergy with symptoms other than hives (due east.grand., angioedema, respiratory distress) or required epinephrine or some other emergency medical intervention: Whatever influenza vaccine advisable for age and wellness status may be administered. If using egg-based IIV4, administer in medical setting under supervision of healthcare provider who can recognize and manage severe allergic reactions
• Moderate or astringent acute illness with or without fever

Vaccine

Flu, cell culture-based inactivated injectable
[(ccIIV4), Flucelvax^® Quadrivalent]

Contraindications^ane

• Severe allergic reaction (due east.yard., anaphylaxis) to any ccIIV of whatever valency, or to any component³ of ccIIV4

Precautions²

• Guillain-Barré syndrome (GBS) within 6 weeks afterward a previous dose of any type of flu vaccine
• Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, RIV, or LAIV of any valency. If using ccIV4, administer in medical setting under supervision of healthcare provider who can recognize and manage astringent allergic reactions. May consult an allergist.
• Moderate or severe acute disease with or without fever

Vaccine

Influenza, recombinant injectable
[(RIV4), Flublok^® Quadrivalent]

Contraindications^ane

• Severe allergic reaction (e.g., anaphylaxis) to whatever RIV of whatsoever valency, or to any componentⁱⁱⁱ of RIV4

Precautions²

• Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine
• Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg- based IIV, ccIIV, or LAIV of any valency. If using RIV4, administrate in medical setting nether supervision of healthcare provider who tin recognize and manage severe allergic reactions. May consult an allergist.
• Moderate or severe acute illness with or without fever

Vaccine

Influenza, live attenuated [LAIV4, Flumist^® Quadrivalent]

Contraindications¹

• Astringent allergic reaction (east.chiliad., anaphylaxis) after previous dose of whatsoever flu vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency)
• Severe allergic reaction (eastward.g., anaphylaxis) to any vaccine component³ (excluding egg)
• Children age two – 4 years with a history of asthma or wheezing
• Anatomic or functional asplenia
• Immunocompromised due to whatever crusade including medications and HIV infection
• Close contacts or caregivers of severely immunosuppressed persons who crave a protected environment
• Pregnancy
• Cochlear implant
• Active communication betwixt the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear or any other cranial CSF leak
• Children and adolescents receiving aspirin or salicylate-containing medications
• Received influenza antiviral medications oseltamivir or zanamivir inside the previous 48 hours, peramivir within the previous five days, or baloxavir within the previous 17 days.

Precautions²

• Guillain-Barré syndrome (GBS) within vi weeks after a previous dose of any type of flu vaccine
• Asthma in persons aged 5 years old or older
• Persons with egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or some other emergency medical intervention: Whatsoever flu vaccine advisable for historic period and health status may be administered. If using LAIV4 (which is egg based), administer in medical setting under supervision of healthcare provider who can recognize and manage severe allergic reactions. May consult an allergist.
• Persons with underlying medical conditions (other than those listed under contraindications) that might predispose to complications after wild-type influenza virus infection [eastward.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)]
• Moderate or astringent acute illness with or without fever

Vaccine

Measles, mumps, rubella (MMR)

Contraindications^ane

• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³
• Severe immunodeficiency (due east.chiliad., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)
• Pregnancy
• Family unit history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent

Precautions²

• Recent (≤eleven months) receipt of antibody-containing claret product (specific interval depends on product)
• History of thrombocytopenia or thrombocytopenic purpura
• Need for tuberculin peel testing or interferon-gamma release assay (IGRA) testing
• Moderate or astringent acute disease with or without fever

Vaccine

Meningococcal ACWY (MenACWY)
[MenACWY-CRM (Menveo^®); MenACWY-D (Menactra^®); MenACWY-TT (MenQuadfi^®)]

Contraindicationsⁱ

• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³
• For MenACWY-D and Men ACWY-CRM only: severe allergic reaction to any diphtheria toxoid– or CRM₁₉₇–containing vaccine
• For MenACWY-TT only: severe allergic reaction to a tetanus toxoid-containing vaccine

Precautionsⁱⁱ

• For MenACWY-CRM but: Preterm nascence if less than historic period nine months
• Moderate or severe acute illness with or without fever

Vaccine

Meningococcal B (MenB)
[MenB-4C (Bexsero^®); MenB-FHbp (Trumenba^®)]

Contraindicationsⁱ

• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine componentⁱⁱⁱ

Precautionsⁱⁱ

• Pregnancy
• For MenB-4C only: Latex sensitivity
• Moderate or severe acute affliction with or without fever

Vaccine

Pneumococcal conjugate (PCV13)

Contraindications^one

• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³
• Severe allergic reaction (east.m., anaphylaxis) to any diphtheria-toxoid– containing vaccine or its component³

Precautions²

• Moderate or severe acute illness with or without fever

Vaccine

Pneumococcal polysaccharide (PPSV23)

Contraindications¹

• Severe allergic reaction (due east.g., anaphylaxis) after a previous dose or to a vaccine component³

Precautions^two

• Moderate or astringent acute illness with or without fever

Vaccine

Poliovirus vaccine, inactivated (IPV)

Contraindications¹

• Astringent allergic reaction (east.yard., anaphylaxis) after a previous dose or to a vaccine componentⁱⁱⁱ

Precautions^two

• Pregnancy
• Moderate or severe acute illness with or without fever

Vaccine

Rotavirus (RV) [RV1 (Rotarix^®), RV5 (RotaTeq^®)]

Contraindications¹

• Severe allergic reaction (eastward.chiliad., anaphylaxis) after a previous dose or to a vaccine componentⁱⁱⁱ
• Astringent combined immunodeficiency (SCID)
• History of intussusception

Precautions²

• Contradistinct immunocompetence other than SCID
• Chronic gastrointestinal disease
• RV1 only: Spina bifida or bladder exstrophy
• Moderate or severe acute illness with or without fever

Vaccine

Tetanus, diphtheria, and acellular pertussis (Tdap)

Tetanus, diphtheria (Td)

Contraindications^ane

• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component³
• For Tdap but: Encephalopathy (e.g., blackout, decreased level of consciousness, prolonged seizures) non attributable to another identifiable cause within 7 days of administration of previous dose of DTP, DTaP, or Tdap

Precautions²

• Guillain-Barré syndrome (GBS) within six weeks subsequently a previous dose of tetanus-toxoid–containing vaccine
• History of Arthus-type hypersensitivity reactions later on a previous dose of diphtheria-toxoid— containing or tetanus-toxoid– containing vaccine; defer vaccination until at least 10 years take elapsed since the last tetanus-toxoid– containing vaccine
• For Tdap only: Progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized
• Moderate or astringent acute illness with or without fever

Contraindications^ane

• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component^three
• Astringent immunodeficiency (e.yard., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)
• Pregnancy
• Family unit history of contradistinct immunocompetence, unless verified clinically or by laboratory testing as immunocompetent

Precautions²

• Recent (≤11 months) receipt of antibody-containing claret production (specific interval depends on product)
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid use of these antiviral drugs for xiv days afterwards vaccination)
• Use of aspirin or aspirin-containing products
• Moderate or severe astute illness with or without fever

1. When a contraindication is nowadays, a vaccine should Not be administered. Kroger A, Bahta L, Hunter P. ACIP Full general All-time Exercise Guidelines for Immunization.
2. When a precaution is nowadays, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta 50, Hunter P. ACIP General Best Practice Guidelines for Immunization.
3. Vaccination providers should bank check FDA-canonical prescribing data for the about consummate and updated information, including contraindications, warnings, and precautions. See Package inserts for U.S.-licensed vaccinesexternal icon.

Vaccines in the Kid and Adolescent Immunization Schedule

Vaccine

Diphtheria, tetanus, and acellular pertussis vaccine

Trade proper name(due south)

Daptacel^®
Infanrix^®

Vaccine

Diphtheria, tetanus vaccine

Trade proper noun(s)

No Trade Name

Vaccine

Haemophilus influenzae type B vaccine

Abridgement(s)

Hib (PRP-T)
Hib (PRP-OMP)

Trade proper noun(s)

ActHIB^®
Hiberix^®
PedvaxHIB^®

Vaccine

Hepatitis A vaccine

Trade name(due south)

Havrix^®
Vaqta^®

Vaccine

Hepatitis B vaccine

Merchandise name(s)

Engerix-B^®
Recombivax HB^®

Vaccine

Human papillomavirus vaccine

Merchandise name(southward)

Gardasil ix^®

Vaccine

Influenza vaccine (inactivated)

Vaccine

Influenza vaccine (alive, attenuated)

Trade name(south)

FluMist^® Quadrivalent

Vaccine

Measles, mumps, and rubella vaccine

Vaccine

Meningococcal serogroups A, C, W, Y vaccine

Abridgement(s)

MenACWY-D
MenACWY-CRM
MenACWY-TT

Trade name(due south)

Menactra^®
Menveo^®
MenQuadfi^®

Vaccine

Meningococcal serogroup B vaccine

Abbreviation(southward)

MenB-4C
MenB-FHbp

Trade proper noun(s)

Bexsero^®
Trumenba^®

Vaccine

Pneumococcal xiii-valent conjugate vaccine

Merchandise name(s)

Prevnar 13^®

Vaccine

Pneumococcal 23-valent polysaccharide vaccine

Merchandise proper noun(due south)

Pneumovax^® 23

Vaccine

Poliovirus vaccine (inactivated)

Vaccine

Rotavirus vaccine

Trade name(due south)

Rotarix^®
RotaTeq^®

Vaccine

Tetanus, diphtheria, and acellular pertussis vaccine

Merchandise name(due south)

Adacel^®
Boostrix^®

Vaccine

Tetanus and diphtheria vaccine

Trade name(s)

Tenivac^®
TDvax™

Vaccine

Varicella vaccine

Combination Vaccines

(Use combination vaccines instead of separate injections when appropriate)

Vaccine

DTaP, hepatitis B, and inactivated poliovirus vaccine

Abbreviation(s)

DTaP-HepB-IPV

Vaccine

DTaP, inactivated poliovirus, andHaemophilus influenzae type B vaccine

Abbreviation(s)

DTaP-IPV/Hib

Vaccine

DTaP and inactivated poliovirus vaccine

Merchandise name(s)

Kinrix^®
Quadracel^®

Vaccine

DTaP, inactivated poliovirus,Haemophilus influenzae type b, and hepatitis B vaccine

Abbreviation(s)

DTaP-IPV-Hib-HepB

Vaccine

Measles, mumps, rubella, and varicella vaccines

This schedule is recommended by the Informational Commission on Immunization Practices (ACIP) and approved past the Centers for Disease Command and Prevention (CDC), American Academy of Pediatrics (AAPexternal icon), American Academy of Family Physicians (AAFPexternal icon)), American College of Obstetricians and Gynecologists (ACOGexternal icon), American College of Nurse-Midwives (ACNMexternal icon), American Academy of Physician Assembly (AAPAexternal icon), and National Association of Pediatric Nurse Practitioners (NAPNAPexternal icon).

The comprehensive summary of the ACIP recommended changes made to the child and boyish immunization schedule tin can be found in the February 18, 2022 MMWR.

How Many Rounds of Shots to Babies Get First 3 Months

Source: https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html

Share this post